NASDAQ:RXRX

Recursion Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy RXRX

*Your capital is at risk

$2.95

-0.0750 (-2.48%)

At Close: Jul 17, 2026

Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis

08:25am, Tuesday, 25'th May 2021

SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across b

2 Hot Biotech IPOs to Consider

06:33am, Tuesday, 27'th Apr 2021

These companies are already making great strides where few dare to tread.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by